FundOS vs Reuben AI

The short answer

Reuben AI is a deal desk. FundOS is a fund back office. Both are marketed as an “operating system for private capital,” and if you read only the homepages you would reasonably conclude they compete head-on. They mostly don’t.

Reuben’s published product runs the pre-investment lifecycle — sourcing, screening, diligence, IC memos, portfolio monitoring and the reports that come out of it. FundOS runs the post-investment lifecycle — the general ledger, NAV with a signed release, capital accounts, capital calls, distributions, K-1s, the LP portal, and the SEC Rule 206(4)-7 compliance program that an examiner asks about. There is genuine overlap in deal CRM, data rooms and diligence, and in that overlap either product will do the job.

So the question is not which is better. It is which half of your problem is unsolved. If your pain is that deals arrive as PDFs and nobody has time to screen them, Reuben is a reasonable buy and we will say so on a call. If your pain is that your NAV lives in a spreadsheet, your administrator is the only one who knows how a number was produced, and your CCO is assembling an exam binder by hand, that is what FundOS was built for.

---

1. At a glance

Reuben column reflects capabilities described on goreuben.com as of September 2026. “Not published” means we could not find it on their public site — it is a statement about their documentation, not a claim that the capability is absent. Where you see it, ask them.

---

2. Where Reuben is strong

A comparison page that finds nothing good in the competitor is not worth reading. Four things Reuben does that we think are genuinely well judged:

• The unified-record framing is correct. Their line about AI agents that “read and write on the same record” is the right architecture for this problem, and most incumbents in this category can’t say it truthfully. We agree with them, which is awkward and worth admitting.
• Unlimited seats. Charging per fund rather than per user is the right shape for a firm where the analyst, the CFO, the CCO and two partners all need to be in the system. Per-seat pricing in fund software is a tax on getting the whole team to use it.
• Deal sourcing has real surface area. A Chrome extension and a public, indexed deal library are top-of-funnel work most vendors don’t bother to do. If sourcing is your bottleneck, that matters.
• A free tier you can actually open. Three deals, no sales call. We don’t have an equivalent, and it is a fair criticism of us.

If the rest of this page reads as one-sided, it is because we are comparing on the axis we chose to build on. On their axis they are a credible product.

---

3. Who keeps the book of record

This is the difference that decides most evaluations, and it is easy to miss because both products use the phrase “single source of truth.” The question to put to any vendor claiming a unified data layer is narrow and unkind:

In FundOS a NAV is a NavRun: computed from the general ledger and the position book, reviewed, and released under maker/checker segregation — the person who prepares it cannot be the person who releases it. Nothing automated can move a number past that gate. Everything downstream reads the released run and nothing else: LP capital-account statements, the ILPA quarterly report, DPI/RVPI/TVPI/IRR, and the figures the Marketing Rule review reconciles a pitch deck against. There is exactly one implementation of the return suite, and if there is no released NAV it returns no multiple at all rather than quietly treating the residual as zero.

We are specific about that last detail because it is the kind of thing that separates a book from a dashboard. A system that reports TVPI of 1.33× when the honest answer is “we cannot value this yet” is not wrong by much, and it is wrong in the direction nobody notices.

Reuben’s public materials describe portfolio monitoring, KPI refreshes and generated LP reports. We found no description of a ledger, a NAV process, a capital account, or a release control. Their pricing meters deals, investment positions and investor records — the units of a CRM, not of a book. If their answer to the NAV question is that it comes in from your administrator, that is a legitimate architecture and you should know it before you buy, because it means the number you show an LP is still produced somewhere you can’t audit.

---

4. The compliance program

Both products use the word compliance and mean different things by it. Reuben’s published compliance capability is KYC / KYB / AML screening across jurisdictions, plus an “allocator compliance” solution page. That is onboarding and sanctions work. It is necessary and it is not the same thing as an adviser’s compliance program.

FundOS ships the Rule 206(4)-7 program itself, as a system of record at the adviser level: written policies, a risk register, 25 registered evidence collectors that test controls against the fund’s own books, findings and remediation state, the annual review, the unified obligation register (side letters and MFN, extracted from the contract text and confirmed against it), Code of Ethics and pay-to-play screening, attestations, Rule 206(4)-1 marketing review, and an SEC exam binder of 13 sections.

Three design choices in there are worth more than the feature list:

• Finding nothing is not a pass. A control test that runs against an empty book returns no_data, not passed, and a control whose only result was no_data is reported untested — it counts as a gap in the program’s own coverage. The natural way to write these checks reports a firm as strongest exactly where it has no records at all. We consider that the single most dangerous bug class in compliance software, and the tests that pin it are the reason to trust the number.
• Coverage divides by every active control, not by the ones that answered. “100% of tested controls passed” over four of thirty-eight controls is true and useless. The dashboard, and the MCP tool behind it, report the untested count alongside the passed count.
• An AI-extracted obligation is not an obligation. A side-letter clause pulled out of an LPA by a model lands unconfirmed, drives no compliance determination, and is never given a due date until a human checks it against the verbatim text. It cannot raise a false overdue alert off a reading nobody verified.

And there is deliberately no AI write tool anywhere in the compliance module — not even an approval-gated one. Finalising an annual review or marking a deck approved for use is a regulatory determination. An agent that can propose it is one release away from one that does it.

---

5. Governance: copy versus artifact

This is the section where we are least comfortable, because Reuben’s positioning here is close to ours and their sentence is better written:

“Every AI output ties back to the deal, the decision, the source data and the approver.”
— goreuben.com, September 2026

We believe the same thing. The difference we’d ask you to test is whether the claim is falsifiable. In FundOS it is two specific mechanisms:

• An enforced approval surface. 25 action kinds are declared human-approval-required as data, and the executor refuses them without an explicit approved status — posting journal entries, creating capital calls, sending LP notices, granting room access, allocating a syndication. Not a setting, not a prompt instruction. A code path with tests that fail the build if a new AI write tool ships ungated.
• An immutable verdict record. Every governed AI output passes a deterministic gate — zero model calls — that writes a durable verdict row: which policy, which validator, what it decided, on what input. That record is the audit trail, and it accrues whether or not the gate is enforcing. To be precise about our own posture: the gate ships in shadow, recording without blocking, until a policy is explicitly promoted after a soak. It is evidence first and a safety net second, and we’d rather say that than imply more.

Aggregate statistics from that gate — policy count, validator count, golden-fixture count and 30-day evaluation volume — are published on our Trust Center, not asserted here. Ask any vendor making a provenance claim to show you the row.

---

6. Agent and MCP access

Both products describe AI agents operating on fund data. The distinction is whether your agents can, or only theirs.

FundOS is an MCP server. 69 tools are live over Streamable HTTP at /mcp and SSE at /mcp/sse, so Claude, ChatGPT, Codex, Cursor or a custom agent connects directly to your fund data and works inside it. Authentication is OAuth 2.1 authorization-code + PKCE with RFC 7591 dynamic client registration — no pre-provisioned client id — or a bearer key for headless agents. Reads are free to call; writes route through the same approval surface a human write does. Every tool’s credit price is published at /.well-known/tools.json so an agent can cost a call before making it, and the catalogue is derived from the live server rather than hand-maintained. There are outbound webhooks with HMAC signatures and stable delivery ids for deduplication, and a generated REST reference at /docs.

On Reuben’s site, MCP appears as a resource topic — a guide page about “MCP and AI tool access for private capital.” We could not find a server endpoint, a tool catalogue, auth documentation, a discovery descriptor, or a public API reference. Writing about MCP and serving it are different commitments, and the second one is checkable from outside the company. Point an MCP client at both and see which one connects.

One more thing that matters if you carry MNPI or data-residency obligations in side letters: FundOS ships a provider seam that routes a model tier to inference hardware you control (an OpenAI-compatible endpoint — Ollama or vLLM). It is off by default and enabled per deployment, and when it is on, a local failure fails the call rather than silently falling back to a hosted vendor. Reuben’s stack is described in third-party listings as GPT-4, LlamaParse and Perplexity, with no residency option we could find.

---

7. Pricing and the transaction fee

Plus, on every plan, a fee “charged on the total transaction value (TTV) of a transaction completed on the platform” on a marginal sliding scale “from 0.75% down to a 0.30% floor.”

Read that carefully before comparing monthly numbers, because the subscription is not the price. At the 0.30% floor, a single $50M transaction carries a six-figure platform fee — more than a decade of the Growth plan. Whether that is reasonable depends entirely on whether the platform is in the transaction path in a way that justifies participating in deal value. Ask them what the fee compensates for, whether it applies to a close they merely recorded, and how TTV is defined for a follow-on, a secondary, a recap or a capital call.

The metering is worth a second look too. If you run a fund with 60 LPs, an allowance of 5 or 20 investor records per month with $25–$35 per record beyond it is a real cost, and it prices you for having investors.

FundOS is a negotiated platform fee plus AI credits at a flat rate, with unlimited users and no fee on your deal value or your investor count. We are generally the more expensive line item at the bottom of a small fund’s first year and materially cheaper the moment you close anything. Current terms are on our pricing page; there is no clause anywhere in our agreement that participates in your economics.

---

8. Which one to choose

They are also not mutually exclusive, and we will not pretend otherwise. A firm running Reuben on the deal desk and FundOS on the book is a coherent stack. What is not coherent is buying either one on the belief that it covers both halves — which is the specific risk created by two companies using the same four words to describe different products.

---

Verify this page

A vendor comparison written by a vendor is worth exactly as much as it is checkable. Every FundOS claim above resolves at a URL you can open without talking to us:

---

Method & sources

Reuben AI information on this page was taken from their public website — goreuben.com homepage, product and solution pages, and pricing page — reviewed September 2026. Quoted material is verbatim from those pages. Their described AI stack (GPT-4, LlamaParse, Perplexity) comes from third-party product directories rather than their own site, so treat it as unconfirmed. We have not been given access to their product, and this page reflects no hands-on evaluation of it — a limitation we would rather state than paper over. Third-party review sites scoring this category are, in our reading, largely unverified content; we have not relied on any of them.

“Not published” in the comparison table means we could not locate the capability on Reuben’s public site as of that date. It is not a claim about their roadmap or their internal build. Software moves; this page will go stale, and when it does the fix is a correction, not a rewrite.

FundOS counts on this page (69 MCP tools, 25 evidence collectors, 13 exam-binder sections, 25 approval-required action kinds) are read from the running system at page load, not typed in — so they cannot drift away from the product. Reuben AI is a trademark of its owner; this page is comparative commentary and implies no affiliation or endorsement.